Business
First-in-Disease Use of Kyverna Therapeutics' KYV-101 in Patients With Progressive Multiple Sclerosis Published in Med
Two patients were treated with KYV-101, a fully human anti-CD19 CAR T-cell product candidate, in Germany as part of a named patient program after failure to
About this update from Kyverna Therapeutics, Inc.
[{"type":"text","content":"Two patients were treated with KYV-101, a fully human anti-CD19 CAR T-cell product candidate, in Germany as part of a named patient program after failure to respond to conventional therapies\nThe treatment resulted in an acceptable safety profile, with no observed clinical signs of early neurotoxicity, warranting larger clinical studies in subjects with multiple sclerosis\nEMERYVILLE, Calif., March 29, 2024 /PRNewswire/ -- Kyverna Therapeutics, Inc. (Kyverna), a patient-centered, clinical-stage biopharmaceutical company focused on developing cell therapies for patients suffering from autoimmune diseases, announces today the publication in Med1, of a report describing the first use of KYV-101, a fully human anti-CD19 chimeric antigen receptor (CAR) T-cell product candidate, in two patients suffering from progressive multiple sclerosis (MS) as part of a named patient program for critically ill patients after both patients failed to respond to conventional therapies.\n\n \n \n \n \n \n \n\n \n\"We are very pleased about offering this potentially paradigm-shifting treatment opportunity to patients that have exhausted other medical recourses,\" said Christoph Heesen, M.D., professor for clinical and rehabilitative MS research at the University Medical Center Hamburg-Eppendorf in Hamburg, Germany, and senior co-author. \"Emerging findings indicating that this approach may affect disease biology in the central nervous system are promising, as preventing disease progression remains one of the most difficult challenges in MS therapy.\"\n\"Exploring the safety profile of CAR T administration in this population and hopefully establishing that it compares favorably to hematopoietic stem cell transplant may bring the cell therapy approach to a larger number of patients in need,\" said Nicolaus Kröger, M.D., professor of Medicine and medical director, Department of Stem Cell Transplantation at the University Medical Center Hamburg-Eppendorf in Hamburg, Germany, and senior co-author. \"If safe administration can be replicated in other patients and efficacy be formally established in clinical trials, this may bring a relevant therapeutic option to patients with MS.\"\n\"We are committed to transforming the standard of treatment for patients living with multiple sclerosis,\" said Peter Maag, Ph.D., chief executive officer of Kyverna. \"The pione...